9CO6
BA.5 spike/Nanosota-9 complex
Summary for 9CO6
Entry DOI | 10.2210/pdb9co6/pdb |
EMDB information | 45771 |
Descriptor | Spike glycoprotein, Nanosota-9, 2-acetamido-2-deoxy-beta-D-glucopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose, ... (4 entities in total) |
Functional Keywords | spike, nanobody, viral protein |
Biological source | Severe acute respiratory syndrome coronavirus 2 More |
Total number of polymer chains | 6 |
Total formula weight | 473773.58 |
Authors | |
Primary citation | Ye, G.,Bu, F.,Saxena, D.,Turner-Hubbard, H.,Herbst, M.,Spiller, B.,Wadzinski, B.E.,Du, L.,Liu, B.,Zheng, J.,Li, F. Discovery of Nanosota-9 as anti-Omicron nanobody therapeutic candidate. Plos Pathog., 20:e1012726-e1012726, 2024 Cited by PubMed Abstract: Omicron subvariants of SARS-CoV-2 continue to pose a significant global health threat. Nanobodies, single-domain antibodies derived from camelids, are promising therapeutic tools against pandemic viruses due to their favorable properties. In this study, we identified a novel nanobody, Nanosota-9, which demonstrates high potency against a wide range of Omicron subvariants both in vitro and in a mouse model. Cryo-EM data revealed that Nanosota-9 neutralizes Omicron through a unique mechanism: two Nanosota-9 molecules crosslink two receptor-binding domains (RBDs) of the trimeric Omicron spike protein, preventing the RBDs from binding to the ACE2 receptor. This mechanism explains its strong anti-Omicron potency. Additionally, the Nanosota-9 binding epitopes on the spike protein are relatively conserved among Omicron subvariants, contributing to its broad anti-Omicron spectrum. Combined with our recently developed structure-guided in vitro evolution approach for nanobodies, Nanosota-9 has the potential to serve as the foundation for a superior anti-Omicron therapeutic. PubMed: 39591462DOI: 10.1371/journal.ppat.1012726 PDB entries with the same primary citation |
Experimental method | ELECTRON MICROSCOPY (3.01 Å) |
Structure validation
Download full validation report
